Marco Meglio

Jacobo Mintzer, MD, MPA, discussed a wide range of Alzheimer disease related topics, including the use of methylphenidate, reactions to AAIC, and the aducanumab approval.

Both short and long sleep durations were associated with worse self-reported cognitive function and multiple lifestyle outcomes, suggesting a U-shaped association.

The 50% responder rate was 58.3% at 12 months and 50.0% at the last visit, with corresponding seizure freedom rates of 23.2% and 20.5%, respectively.

Impel’s agent is designed to deliver a lower dose of dihydroergotamine mesylate (DHE) compared with other nasally administered products.

The web-implemented algorithm misclassified and misdiagnosed seizures in only 16.8% of the patients with epilepsy—lower than rates previously reported in the literature.

The director of the Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology discussed unmet needs of care for patients with neuromyelitis optica spectrum disorder.

Although headache infusion centers were generally open during the standard business hours, few headache infusion centers were open after hours and on weekends.

This was the first time that progression of cognitive fluctuations in patients with Lewy body dementia had been systematically investigated using a clinical rating scale.

Cluster analysis classified 29.5% more of the sample with mild cognitive impairment compared to the Alzheimer’s Disease Research Center’s consensus diagnosis.

After receiving original approval in 2016, brivaracetam is now available as both monotherapy or adjunctive therapy to treat partial-onset seizures in pediatrics 1 month of age and older.

The director of Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology provided context on challenges within the NMOSD space and what’s next following the first-approved therapies.

The results support continued development of tolebrutinib 60 mg in phase 3 trials for MS, based on the well-established relationship between reductions of Gadolinium-enhancing lesions and relapse rates.

The Swedish treatment strategy—one of mostly induction—was associated with a 24% reduction in the rate of reaching EDSS score of 3 and a 25% reduction in the rate of reaching an EDSS score of 4.

The rate of patients demonstrating impairment on cognitive assessments such as CVLTII, BVMT-R, and SDMT significantly decreased after treatment with fingolimod at 5-year follow-up.

The director of the Cerebrovascular Center at Cleveland Clinic provided context on why stroke systems should incorporate IV tPA as early as possible to treat emergent large vessel occlusion.

At weeks 54, 106, and 145, most of both age groups achieved treatment success on both the CGIC and PGIC, with numerically higher percentages observed in younger vs older participants.

For the primary end point, the 3 dose options atogepant (AbbVie) were associated with a reduction ranging from 3.9 to 4.2 days in the mean number of headache days per month for those with episodic migraine.

Lesions in the canalicular and intracranial optic nerve, area postrema, medulla, and cervical spinal cord were prominent in patients with aquaporin-4–NMOSD.

The innovative nonsurgical device has previously received market authorization to treat gait deficit due to mild-to-moderate symptoms from multiple sclerosis.

The agent’s safety profile has been studied in more than 1200 individuals to date across several inflammatory diseases, with data indicating that the high selectivity of fenebrutinib may limit off-target effects.

Patients with focal seizures showed a median 25.2% reduction in the frequency of focal seizures, the most common seizure type in patients with tuberous sclerosis complex.

Multivariable logistic regression models found age to be the only characteristic associated with the risk of CELs at baseline in all datasets, with a higher age associated with a lower risk of CELs.

The director of the Comprehensive Center for Brain Health at the University of Miami Miller School of Medicine provided context on greenhouse spaces and their preventive benefits in Alzheimer disease.

Microvesicles excellently discriminated between the relapsing-remitting MS and control groups and between radiologically isolated syndrome and unspecific brain lesions.

Investigators identified 4 susceptible loci with large effect sizes, one of which has previously been associated with migraine.

Individuals with chronic and episodic migraine saw improvements in patient-reported outcomes such as MSQoL, EQ-5D-5L, PGIC, WPAI, and the 9-Item Patient Health Questionnaire.

Patients with AQP4+NMOSD with long cord lesion showed higher annualized atrophy rate of normalized grey matter volume compared with those without long cord lesion.

After years of only off-label, wake-promoting therapies available for use, the FDA has approved the first treatment for idiopathic hypersomnia, JZP-258 (Xywav; Jazz).

The association of increased EVT rates was noted with the initiation of online training and EMS dissemination of the policy in September 2018, 2 months in advance of formal implementation of prehospital protocol.

Two unblinded interim analyses by the Data Monitoring Committee are planned to assess the futility of reldesemtiv, with the first occurring 12 weeks after one-third of the sample size is randomized.